DOCSLIB.ORG

Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study Open Access Research BMJ Open: first published as 10.1136/bmjopen-2016-011322 on 6 June 2016. Downloaded from Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study Jason C Hsu,1 Christine Y Lu2 To cite: Hsu JC, Lu CY. ABSTRACT Strengths and limitations of this study Longitudinal trends in use Objectives: Some targeted therapies have improved and costs of targeted survival and overall quality of cancer care generally, but ▪ therapies for common This is the first study to examine the national these increasingly expensive medicines have led to cancers in Taiwan: a trend in use and costs of targeted therapies for retrospective observational increases in pharmaceutical expenditure. This study treatment of cancer in Taiwan. study. BMJ Open 2016;6: examined trends in use and expenditures of ▪ We also determined which cancer types e011322. doi:10.1136/ antineoplastic agents in Taiwan, and estimated market accounted for the highest use of targeted therap- bmjopen-2016-011322 shares by prescription volume and costs of targeted ies in Taiwan, from 2009 to 2012. therapies over time. We also determined which cancer ▪ Data were retrieved from Taiwan’s National ▸ Prepublication history and types accounted for the highest use of targeted Health Insurance Research Database with nearly additional material is therapies. 99% of the Taiwanese population (around 23 available. To view please visit Design: This is a retrospective observational study million residents) enrolled and 97% of hospitals the journal (http://dx.doi.org/ focusing on the utilisation of targeted therapies for and clinics throughout the country included. 10.1136/bmjopen-2016- treatment of cancer. ▪ A time series design with Autoregressive 011322). Setting: The monthly claims data for antineoplastic Integrated Moving Average (ARIMA) models was agents were retrieved from Taiwan’s National Health used in this study, to estimate the trends in Insurance Research Database (2009–2012). market shares by prescription volume and costs Received 29 January 2016 of targeted therapies. Revised 28 April 2016 Main outcome measures: We calculated market shares by prescription volume and costs for each class ▪ Owing to the lack of patient-level data, this study Accepted 18 May 2016 http://bmjopen.bmj.com/ of antineoplastic agent by cancer type. Using a time did not investigate the use of combination treat- series design with Autoregressive Integrated Moving ments; these need to be examined in future Average (ARIMA) models, we estimated trends in use studies. and costs of targeted therapies. Results: Among all antineoplastic agents, use of targeted therapies grew from 6.24% in 2009 to this percentage is expected to increase.12In 12.29% in 2012, but their costs rose from 26.16% to Taiwan, cancer is a leading cause of mortality 41.57% in that time. Monoclonal antibodies and and the annual number of patients with protein kinase inhibitors contributed the most cancer has been growing.3 In 2011, ∼92 682 on October 6, 2021 by guest. Protected copyright. (respectively, 23.84% and 16.12% of costs for individuals were diagnosed with cancer – antineoplastic agents in 2012). During 2009 2012, (male: 56%, female: 44%). Most common lung (44.64% of use; 28.26% of costs), female breast cancers in Taiwan were female breast cancer, (16.49% of use; 27.18% of costs) and colorectal (12.11% of use; 13.16% of costs) cancers accounted colorectal cancer, liver cancer, lung cancer 1 for the highest use of targeted therapies. and prostate cancer. In the same year, School of Pharmacy and ∼ Institute of Clinical Pharmacy Conclusions: In Taiwan, targeted therapies are 42 559 patients died of cancer (male: 64%, and Pharmaceutical Sciences, increasingly used for different cancers, representing a female: 36%), accounting for 28% of all College of Medicine, National substantial economic burden. It is important to deaths. Major cancers causing mortality were Cheng Kung University, establish mechanisms to monitor their use and lung cancer, liver cancer, colorectal cancer, Tainan City, Taiwan 2 outcomes. female breast cancer and oral/pharyngeal Department of Population 3 Medicine, Harvard Medical cancer. School and Harvard Pilgrim Cancer care has improved substantially and Health Care Institute, Boston, INTRODUCTION the average life expectancy has increased in Massachusetts, USA Cancer is a major public health issue glo- the past two decades, due to preventative 4 5 Correspondence to bally. Approximately 7.4 million people die strategies, early diagnosis, advances in Dr Jason C Hsu; of cancer each year worldwide, which medical technologies (including surgery and 6 [email protected] accounts for 13% of all-cause mortality, and medications) and clinical management. Hsu JC, Lu CY. BMJ Open 2016;6:e011322. doi:10.1136/bmjopen-2016-011322 1 Open Access Traditionally, chemotherapies are the main medicines for increasingly adopting patient access schemes (also BMJ Open: first published as 10.1136/bmjopen-2016-011322 on 6 June 2016. Downloaded from cancer. But these drugs are not specific to the target, and known as managed entry agreements or risk-sharing therefore often cause serious adverse effects including arrangements) to enable patient access to needed medi- neutropaenia, anaemia and thrombocytopaenia.7 In the cines, while ensuring that financing systems are sustain- last decade, however, many new anticancer drugs, so able.35 36 The performance of managed entry called targeted therapies,8 have become available. These agreements, however, is largely unknown because most drugs differ from standard chemotherapy in that they have not been evaluated.33 Major challenges at present target specific vulnerable nodes in molecular pathways;910 for many health systems include determining what pro- thus, they are generally less toxic than traditional che- portion of the healthcare budget should be allocated for motherapies.11 For some cancers, targeted therapies are treatment of cancer, including budget for targeted ther- becoming the main treatments, for example, trastuzumab apies, and designing and implementing new models for for early-stage and human epidermal growth factor recep- pricing, reimbursement, funding and utilisation deci- tor 2 (HER2) positive metastatic breast cancer.12 13 sions for cancer medicines.37 Dozens of targeted therapies have become available in In Taiwan, economic evaluation has, since 2007, been recent years and many are in the drug development pipe- part of the health technology assessment to evaluate line.14 While some have demonstrated improvements in new drugs, to determine decisions for coverage by the progression-free survival, other agents have provided National Health Insurance (NHI).38 39 In addition, prior minimal or no gains in overall survival; for instance, sora- authorisation is required for many cancer medicines, fenib, sunitinib, temsirolimus, everolimus, bevacizumab, especially for targeted therapies with high reimburse- pazopanib and axitinib for renal cell cancer.15 ment prices. An application for prior authorisation can Changes in the cancer treatment paradigm are accom- be made to the NHI system, and the drug will be reim- panied by significant economic consequences. Targeted bursed if authorisation is given.40 For instance, accord- therapies are expensive, typically costing from US$4500 ing to ‘Directions of Drug Restricted Benefit for to >US$10 000 per treatment month, even if they dem- National Health Insurance’, two targeted therapies, gefi- onstrate only improvements in progression-free survival tinib and erlotinib, for treatment of lung cancer, have – without marked gains in overall survival.15 20 The been reimbursed since 2004 and 2007, respectively. In increasing costs of new targeted cancer therapies the beginning, both were restricted to be used as third- have risen 10 times during the last decade.21 Given the line treatment, that is, patients must first have been number of new cancer medicines in development and treated with platinum and docetaxel or paclitaxel likely continual increases in drug prices, pricing of new chemotherapy, and must have had locally advanced or anticancer drugs is a real concern for accessibility and metastatic adenocarcinoma of the lung.41 affordability across all countries.15 22 23 Some have sug- Little is known about the utilisation and economic gested that a minimum of improvement in median sur- impacts of targeted cancer therapies in Taiwan. The aim http://bmjopen.bmj.com/ vival of at least 3–6 months by new cancer medicines of our longitudinal analyses was to address this gap by compared with current standards is required for the new examining the recent trend in utilisation and expendi- agent to be considered as advanced and funded at tures of cancer treatments, including targeted therapies, higher prices.24 Furthermore, because of the much higher in Taiwan. We also identified which types of cancer costs of targeted therapies compared with conventional accounted for the highest use of targeted therapies. chemotherapy—while the number of eligible patients (due to molecular subtyping) for individual agents is generally small—in aggregate, costs of targeted therapies as a group METHODS on October 6, 2021 by guest. Protected copyright. is an important contributor to growing expenditures for Data sources cancer treatments and an important issue of sustainability Taiwan’s National Health Insurance Research Database – for all healthcare systems.25 27 provided data for this study. The
Load more

Recommended publications
  • Treatment of Localized Extranodal NK/T Cell Lymphoma, Nasal Type: a Systematic Review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim*
    Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Open Access Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim* Abstract Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non- anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL. Keywords: Extranodal NK/T cell lymphoma, Chemoradiotherapy, Localized disease Background Treatment for newly diagnosed patients with localized Extranodal natural killer/T cell lymphoma (ENKTL), nasal nasal ENKTL type, is a rare subtype of non-Hodgkin lymphoma [1].
    [Show full text]
  • LYSODREN Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Central Nervous System (CNS) Toxicity: Plasma concentrations LYSODREN safely and effectively. See full prescribing information for exceeding 20 mcg/mL are associated with a greater incidence of toxicity. LYSODREN. (5.2) • Adrenal Insufficiency: Institute steroid replacement as clinically LYSODREN® (mitotane) tablets, for oral use indicated. Measure free cortisol and corticotropin (ACTH) levels to Initial U.S. Approval: 1970 achieve optimal steroid replacement. (5.3) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR reproductive potential of the potential risk to a fetus and use of effective SEVERE TRAUMA contraception. (5.4, 8.1, 8.3) See full prescribing information for complete boxed warning. • Ovarian Macrocysts in Premenopausal Women: Advise women to seek medical advice if they experience gynecological symptoms such as In patients taking LYSODREN, adrenal crisis occurs in the setting of vaginal bleeding and/or pelvic pain. (5.5) shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue -------------------------------ADVERSE REACTIONS------------------------------ LYSODREN until recovery. (2.2, 5.1) Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash. (6) ---------------------------INDICATIONS AND USAGE---------------------------- LYSODREN is an adrenal cytotoxic agent indicated for the treatment of To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers inoperable, functional or nonfunctional, adrenal cortical carcinoma. (1) Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    [Show full text]
  • EDP & Mitotane Protocol
    THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHA HANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical carcinoma ECOG performance status of 0 - 2 All possible tumour tissues should be surgically removed from large metastatic masses before mitotane administration is instituted. This is necessary to minimise the possibility of infarction and haemorrhage in the tumour due to a rapid cytotoxic effect of mitotane Exclusion criteria: Previous complete cumulative doses of anthracyclines Decompensated heart failure (ejection fraction <50%) Unstable angina, uncontrolled cardiac arrhythmias, MI or revascularisation procedure within last 6 months Dosage: Drug Dosage Route Frequency Etoposide 100mg/m2 IV Daily on days 2, 3 and 4 of each cycle Doxorubicin 40mg/m2 IV Once only on day 1 of each cycle Cisplatin 40mg/m2 IV Daily on days 3 and 4 of each cycle Variable, max Continuous, started a week prior to IV Mitotane PO 6g daily chemotherapy if not already taking With cycles repeated at 28 day intervals until disease progression Supportive treatments: Domperidone 10mg oral tablets maximum 3 times a day or as required Issue Date: May 2017 Page 1 of 8 Protocol reference: MPHAHANEDP 1 Authorised by: Drugs & Therapeutics Author: Helen Flint Committee & Dr D Husband Version No: 1.0 THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Extravasation risk: Doxorubicin is a vesicant and must be observed during administration. Follow the procedure for anthracycline extravasation. Erythematous streaking (a histamine release phenomenon) along the vein proximal to the site of injection has been reported, and must be differentiated from an extravasation event.
    [Show full text]
  • Modifications on the Basic Skeletons of Vinblastine and Vincristine
    Molecules 2012, 17, 5893-5914; doi:10.3390/molecules17055893 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Modifications on the Basic Skeletons of Vinblastine and Vincristine Péter Keglevich, László Hazai, György Kalaus and Csaba Szántay * Department of Organic Chemistry and Technology, University of Technology and Economics, H-1111 Budapest, Szt. Gellért tér 4, Hungary * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel: +36-1-463-1195; Fax: +36-1-463-3297. Received: 30 March 2012; in revised form: 9 May 2012 / Accepted: 10 May 2012 / Published: 18 May 2012 Abstract: The synthetic investigation of biologically active natural compounds serves two main purposes: (i) the total synthesis of alkaloids and their analogues; (ii) modification of the structures for producing more selective, more effective, or less toxic derivatives. In the chemistry of dimeric Vinca alkaloids enormous efforts have been directed towards synthesizing new derivatives of the antitumor agents vinblastine and vincristine so as to obtain novel compounds with improved therapeutic properties. Keywords: antitumor therapy; vinblastine; vincristine; derivatives 1. Introduction Vinblastine (1) and vincristine (2) are dimeric alkaloids (Figure 1) isolated from the Madagaskar periwinkle plant (Catharantus roseus), exhibit significant cytotoxic activity and are used in the antitumor therapy as antineoplastic agents. In the course of cell proliferation they act as inhibitors during the metaphase of the cell cycle and by binding to the microtubules inhibit the development of the mitotic spindle. In tumor cells these agents inhibit the DNA repair and the RNA synthesis mechanisms, blocking the DNA-dependent RNA polymerase. Molecules 2012, 17 5894 Figure 1.
    [Show full text]
  • National Dose Banding Table – Single Container
    National Dose Banding Table – Single Container Arsenic Trioxide Cisplatin Cladribine (Leustat) Strength of raw material 1 mg/mL Example drug(s) Idarubicin (after reconstitution if required) Mitomycin Vinblastine Vincristine See table usage notes below regarding ‘single container’ and ‘multiple syringe’ tables. Master Bands and Ranges This table is intended to be in a format useful for electronic prescribing systems. Use To (A) if your system will round UP for doses on the step between two bands. Use To (B) if your system will round DOWN for doses on the step between two bands. Band Range (mg) Band Dose Variance (percent) From ≥ To (A) < To (B) ≤ (mg) Below Above 0.21 0.23 0.22 0.22 5 -4 0.23 0.25 0.24 0.24 4 -4 0.25 0.27 0.26 0.26 4 -4 0.27 0.29 0.28 0.28 4 -3 0.29 0.32 0.31 0.3 3 -6 0.32 0.36 0.35 0.34 7 -5 0.36 0.40 0.39 0.38 6 -5 0.40 0.44 0.43 0.42 5 -5 0.44 0.49 0.48 0.46 5 -6 0.49 0.55 0.54 0.52 6 -5 0.55 0.61 0.60 0.58 6 -5 0.61 0.68 0.67 0.64 5 -6 0.68 0.76 0.75 0.72 6 -5 0.76 0.85 0.84 0.8 5 -6 0.85 0.95 0.94 0.9 6 -5 0.95 1.05 1.04 1 5 -5 1.05 1.15 1.14 1.1 5 -4 1.15 1.25 1.24 1.2 4 -4 1.25 1.35 1.34 1.3 4 -4 1.35 1.45 1.44 1.4 4 -3 1.45 1.55 1.54 1.5 4 -3 1.55 1.65 1.64 1.6 3 -3 1.65 1.75 1.74 1.7 3 -3 1.75 1.90 1.89 1.8 3 -5 1.90 2.10 2.09 2 5 -5 2.10 2.30 2.29 2.2 5 -4 2.30 2.50 2.49 2.4 4 -4 2.50 2.70 2.69 2.6 4 -4 2.70 2.90 2.89 2.8 4 -3 2.90 3.10 3.09 3 4 -3 3.10 3.30 3.29 3.2 3 -3 3.30 3.50 3.49 3.4 3 -3 3.50 3.80 3.79 3.6 3 -5 3.80 4.20 4.19 4 5 -5 4.20 4.60 4.59 4.4 5 -4 Chemotherapy Dose Standardisation Band Range (mg)
    [Show full text]
  • Side Effects of Targeted Therapy
    Side effects of Targeted Therapy Joanne Bird Clare Warnock NIHR Research Fellow Senior Project Nurse Types of Anti Cancer Therapy Biological Therapies Cytotoxic Drugs • Hormone therapies Ongoing research (Chemotherapy) • Goserelin/Zoladex.® • Anti cancer vaccines • Antibiotics • Tamoxifen • Blood cell growth factors • Monoclonal Antibodies • Blood vessel growth • Antimetabolites • Herceptin blockers • Retuximab • IFN/IL2 • Alkylating agents • Bevacizumab (avastin) • Gene therapy • Radioactive substance • Vinca Alkaloids • Cancer growth inhibiters carriers (conjugated MABs) – Tyrosine Kinase Inhibitors • Anthracyclines – Proteasome inhibitors • Drug carriers – mTOR inhibitors – PI3K inhibitors – Histone deacetylase inhibitors – Hedgehog pathway blockers • Pro cytotoxic Drugs • Capecitabine Tyrosine Kinase Inhibitors • How many do you know!!!!! TKIs • Afatanib • Imatinib • Axitinib • Lapatinib • Bosutinib • Nilotinib • Crizotinib • Pazopanib • Dabrafenib • Regorafenib • Dasatinib • Sorafenib • Erlotinib • Sunitinib • Gefitinib • Trametinib Principles • Growth factor receptors play a role on the normal processes of cell growth and development. – In some cancers these growth receptors are over- expressed leading to unregulated cell growth. • Molecular pathways involved in cancer cell proliferation are identified • Drugs are developed to act on these pathways Symptom grading • Standardised assessment – objective – My small and your small may be different! • Effective communication and documentation • Accurate evaluation of new treatments in
    [Show full text]
  • 996.Full-Text.Pdf
    Published OnlineFirst April 6, 2010; DOI: 10.1158/1535-7163.MCT-09-0960 Research Article Molecular Cancer Therapeutics Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer Kae Hashimoto1, Shan Man1, Ping Xu1, William Cruz-Munoz1, Terence Tang1, Rakesh Kumar3, and Robert S. Kerbel1,2 Abstract Low-dose metronomic chemotherapy has shown promising activity in many preclinical and some phase II clinical studies involving various tumor types. To evaluate further the potential therapeutic impact of met- ronomic chemotherapy for ovarian cancer, we developed a preclinical model of advanced human ovarian cancer and tested various low-dose metronomic chemotherapy regimens alone or in concurrent combination with an antiangiogenic drug, pazopanib. Clones of the SKOV-3 human ovarian carcinoma cell line expressing a secretable β-subunit of human choriogonadotropic (β-hCG) protein and firefly luciferase were generated and evaluated for growth after orthotopic (i.p.) injection into severe combined immunodeficient mice; a high- ly aggressive clone, SKOV-3-13, was selected for further study. Mice were treated beginning 10 to 14 days after injection of cells when evidence of carcinomatosis-like disease in the peritoneum was established as assessed by imaging analysis. Chemotherapy drugs tested for initial experiments included oral cyclophos- phamide, injected irinotecan or paclitaxel alone or in doublet combinations with cyclophosphamide; the re- sults indicated that metronomic cyclophosphamide had no antitumor activity whereas metronomic irinotecan had potent activity. We therefore tested an oral topoisomerase-1 inhibitor, oral topotecan, at optimal biological dose of 1 mg/kg/d. Metronomic oral topotecan showed excellent antitumor activity, the extent of which was significantly enhanced by concurrent pazopanib, which itself had only modest activity, with 100% survival values of the drug combination after six months of continuous therapy.
    [Show full text]
  • Assessment of Overall Survival, Quality of Life, And
    Supplementary Online Content Salas-Vega S, Iliopoulos O, Mossialos E. Assesment of overall survival, quality of life, and safety benefits associated with new cancer medicines [published online December 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.4166 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 eTable 2. Regulatory evidence in support of classification of drug clinical benefits eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits eTable 3. Interagency agreement–Krippendorff’s alpha coefficients eMethods This supplementary material has been provided by the authors to give readers additional information about their work. Online-Only Supplement © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 Clinical value of cancer medicines Contents eExhibits ......................................................................................................................................................... 3 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 (Summary of eTable 2) ................................................................................................................... 3 eTable 2. Regulatory evidence in support of classification of drug clinical benefits ....................... 6 eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, Firas El Chaer 4, James A
    Journal of Clinical Medicine Article Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Ciera L. Patzke 1, Alison P. Duffy 1,2, Vu H. Duong 1,3, Firas El Chaer 4, James A. Trovato 2, Maria R. Baer 1,3, Søren M. Bentzen 1,3 and Ashkan Emadi 1,3,* 1 Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; [email protected] (C.L.P.); aduff[email protected] (A.P.D.); [email protected] (V.H.D.); [email protected] (M.R.B.); [email protected] (S.M.B.) 2 School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA; [email protected] 3 School of Medicine, University of Maryland, Baltimore, MD 21201, USA 4 School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-328-2596 Received: 10 January 2020; Accepted: 13 February 2020; Published: 16 February 2020 Abstract: Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027).
    [Show full text]
  • Targeting the Mitochondrial Metabolic Network: a Promising Strategy in Cancer Treatment
    International Journal of Molecular Sciences Review Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment Luca Frattaruolo y , Matteo Brindisi y , Rosita Curcio, Federica Marra, Vincenza Dolce and Anna Rita Cappello * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy; [email protected] (L.F.); [email protected] (M.B.); [email protected] (R.C.); [email protected] (F.M.); [email protected] (V.D.) * Correspondence: [email protected] These authors contributed equally and should be considered co-first authors. y Received: 31 July 2020; Accepted: 19 August 2020; Published: 21 August 2020 Abstract: Metabolic reprogramming is a hallmark of cancer, which implements a profound metabolic rewiring in order to support a high proliferation rate and to ensure cell survival in its complex microenvironment. Although initial studies considered glycolysis as a crucial metabolic pathway in tumor metabolism reprogramming (i.e., the Warburg effect), recently, the critical role of mitochondria in oncogenesis, tumor progression, and neoplastic dissemination has emerged. In this report, we examined the main mitochondrial metabolic pathways that are altered in cancer, which play key roles in the different stages of tumor progression. Furthermore, we reviewed the function of important molecules inhibiting the main mitochondrial metabolic processes, which have been proven to be promising anticancer candidates in recent years. In particular, inhibitors of oxidative phosphorylation (OXPHOS), heme flux, the tricarboxylic acid cycle (TCA), glutaminolysis, mitochondrial dynamics, and biogenesis are discussed. The examined mitochondrial metabolic network inhibitors have produced interesting results in both preclinical and clinical studies, advancing cancer research and emphasizing that mitochondrial targeting may represent an effective anticancer strategy.
    [Show full text]
  • Vinca Major, V. Minor
    Vinca major, V. minor INTRODUCTORY DISTRIBUTION AND OCCURRENCE BOTANICAL AND ECOLOGICAL CHARACTERISTICS FIRE EFFECTS AND MANAGEMENT MANAGEMENT CONSIDERATIONS APPENDIX: FIRE REGIME TABLE REFERENCES INTRODUCTORY AUTHORSHIP AND CITATION FEIS ABBREVIATION NRCS PLANT CODE COMMON NAMES TAXONOMY SYNONYMS LIFE FORM FEDERAL LEGAL STATUS OTHER STATUS Common periwinkle. Photo by Dan Tenaglia, Missouriplants.com, Bugwood.org AUTHORSHIP AND CITATION: Stone, Katharine R. 2009. Vinca major, V. minor. In: Fire Effects Information System, [Online]. U.S. Department of Agriculture, Forest Service, Rocky Mountain Research Station, Fire Sciences Laboratory (Producer). Available: http://www.fs.fed.us/database/feis/ [ 2010, February 8]. FEIS ABBREVIATION: VINSPP VINMAJ VINMIN NRCS PLANT CODE [106]: VIMA VIMI2 COMMON NAMES: bigleaf periwinkle big periwinkle greater periwinkle large periwinkle periwinkle vinca common periwinkle lesser periwinkle periwinkle vinca TAXONOMY: The genus name for periwinkles is Vinca L. (Apocynaceae). This review summarizes information on the following periwinkle species [29,42,61,78,113]: Vinca major L., bigleaf periwinkle Vinca minor L., common periwinkle In this review, species are referred to by their common names, and "periwinkles" refers to both species. Numerous periwinkle cultivars are available [30,66]. SYNONYMS: None LIFE FORM: Vine-forb FEDERAL LEGAL STATUS: None OTHER STATUS: Information on state-level noxious weed status of plants in the United States is available at Plants Database. DISTRIBUTION AND OCCURRENCE SPECIES: Vinca major, V. minor GENERAL DISTRIBUTION HABITAT TYPES AND PLANT COMMUNITIES GENERAL DISTRIBUTION: Bigleaf periwinkle is native to Mediterranean Europe [1,4], Asia Minor [1], and northern Africa (review by [10]). Common periwinkle is native across all of continental Europe as far north as the Baltic States [86].
    [Show full text]